Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

NCT04700072 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Pembrolizumab/Quavonlimab
DRUG: Lenvatinib

Sponsor

Merck Sharp & Dohme LLC